4363-99-9 Usage
Description
(3-THIOPHEN-2-YLMETHYL-5-THIOXO-1,5-DIHYDRO-[1,2,4]TRIAZOL-4-YL)-ACETIC ACID is a heterocyclic chemical compound with potential pharmacological properties. It features a thiophene ring and a [1,2,4]triazol-4-yl moiety, along with a thioxo group that may contribute to its reactivity and interaction with biological targets. The presence of the acetic acid group enhances its solubility and suitability for pharmaceutical formulations. (3-THIOPHEN-2-YLMETHYL-5-THIOXO-1,5-DIHYDRO-[1,2,4]TRIAZOL-4-YL)-ACETIC ACID's unique structure and functional groups make it a promising candidate for medicinal chemistry and pharmaceutical research, with the potential to be developed into a drug.
Used in Pharmaceutical Industry:
(3-THIOPHEN-2-YLMETHYL-5-THIOXO-1,5-DIHYDRO-[1,2,4]TRIAZOL-4-YL)-ACETIC ACID is used as a potential drug candidate for its pharmacological properties. (3-THIOPHEN-2-YLMETHYL-5-THIOXO-1,5-DIHYDRO-[1,2,4]TRIAZOL-4-YL)-ACETIC ACID's structure and functional groups suggest that it may have therapeutic applications, warranting further research and development to explore its efficacy and safety in treating various medical conditions.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (3-THIOPHEN-2-YLMETHYL-5-THIOXO-1,5-DIHYDRO-[1,2,4]TRIAZOL-4-YL)-ACETIC ACID serves as a subject for investigation to understand its interactions with biological targets. (3-THIOPHEN-2-YLMETHYL-5-THIOXO-1,5-DIHYDRO-[1,2,4]TRIAZOL-4-YL)-ACETIC ACID's reactivity and potential to bind with specific receptors or enzymes make it an interesting subject for studying its mechanism of action and optimizing its properties for drug development.
Used in Drug Formulation Development:
(3-THIOPHEN-2-YLMETHYL-5-THIOXO-1,5-DIHYDRO-[1,2,4]TRIAZOL-4-YL)-ACETIC ACID is used in the development of pharmaceutical formulations due to its solubility-enhancing acetic acid moiety. This feature allows for the creation of more effective drug delivery systems, improving the compound's bioavailability and overall therapeutic potential.
Check Digit Verification of cas no
The CAS Registry Mumber 4363-99-9 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 4,3,6 and 3 respectively; the second part has 2 digits, 9 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 4363-99:
(6*4)+(5*3)+(4*6)+(3*3)+(2*9)+(1*9)=99
99 % 10 = 9
So 4363-99-9 is a valid CAS Registry Number.
4363-99-9Relevant articles and documents
Discovery, synthesis and molecular substantiation of N-(benzo[d]thiazol-2-yl)-2-hydroxyquinoline-4-carboxamides as anticancer agents
Bindu,Vijayalakshmi,Manikandan
, (2019/08/07)
The effort was taken to develop a series of benzothiazole and quinoline fused bioactive compounds obtained through a four-step synthetic route using a range of substituted acetoacetanilides. Achieved N-(benzo[d]thiazol-2-yl)-2-hydroxyquinoline-4-carboxamides (6a-l) were produced up to 96% of yield while the eco-friendly p-TSA used as a catalyst. Further, the anticancer activity of these compounds was determined using a range of cancer cell lines starting from MCF-7 (Breast cancer), HCT-116 (Colon cancer), PC-3 & LNCaP (Prostate) and SK-HEP-1 (Liver cancer). Present study compounds were also testified for antioxidant properties prior to anticancer studies since the Reactive Oxygen Species (ROS) being vital in cancer development. To determine the cell membrane stability effects of the compounds, human red blood cells (HRBC) based membrane protection assay was determined. In the results, compounds 6a-l were able to produce a dominated result values over PC3 cell lines (Prostate cancer) than the other cell lines used in this study. Since the connectivity of human germ cell alkaline phosphatase (hGC-ALP) in the development of prostate cancer is known, the most active compounds were evaluated for the hGC-ALP inhibition in order to ensure a mechanism of anticancer action of these compounds. The mode of interaction and binding affinity of these compounds was also investigated by a molecular docking study. In the results, 6d, 6i, 6k, and 6l were found with least IC50 values 0.075 μM and highest relative activity of 92%, 90%, and 96% respectively. The need for further animal model evaluation and pre-clinical studies recognized.